Floatz logo

SAR-BISPSMA, CU-64

Cryotherapy

Clarity Pharmaceuticals LtdSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Cryotherapy cohort.

Asset / SponsorPhaseRating
DEXKETOPROFEN
Gdansk University of Physical Education and Sport
N/AD
METAMIZOLE
Gdansk University of Physical Education and Sport
N/AD
NEPENTHE
Gdansk University of Physical Education and Sport
N/AD

Same molecule, other indications

SAR-BISPSMA, CU-64 is also rated in:

prostate neoplasmDormant
B
Indicative ·
59 / 100
View asset →
prostate cancerDormant
B
Indicative ·
58 / 100
View asset →
metastatic prostate carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →